Five-year survival rates approaching 30% have been seen for some patients with advanced non-small cell lung cancer treated with pembrolizumab, according to the latest results from the KEYNOTE-1 study. Presented at ASCO 2019, the new findings show that life expectancy for some patients with the disease can now be measured in years rather than months ...
1 in 4 patients with advanced NSCLC alive at 5 years with immunotherapy
By Michael Woodhead
2 Jun 2019